Meeting
2016 Genitourinary Cancers Symposium
The prevalence of objectively measurable disease in phase III trials of metastatic castration-resistant prostate cancer (mCRPC).
Authors
Ankit Madan
University of Alabama, Hoover, AL
Ankit Madan , Mary K Baker , Jori E May , Gurudatta Naik , Sejong Bae , Guru Sonpavde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 215)
DOI
10.1200/jco.2016.34.2_suppl.215
Abstract #
215
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration resistant prostate cancer (mCRPC) treated on SWOG Study S0421.
First Author: Gregory Russell Pond
Poster
2024 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.
First Author: Umang Swami
Poster
2023 ASCO Genitourinary Cancers Symposium
AtezoCab: A phase II study of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with non-measurable disease (NMD).
First Author: Umang Swami
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel P. Petrylak